Metsera (NASDAQ:MTSR) Given “Market Perform” Rating at Leerink Partners

Leerink Partners reiterated their market perform rating on shares of Metsera (NASDAQ:MTSR) in a research note published on Wednesday, MarketBeat Ratings reports. Leerink Partners currently has a $57.00 price target on the stock, down from their prior price target of $77.00.

Several other equities analysts have also issued reports on MTSR. Guggenheim lifted their price target on shares of Metsera from $56.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, June 10th. Wall Street Zen downgraded shares of Metsera from a “hold” rating to a “sell” rating in a research note on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Metsera in a research report on Wednesday, September 3rd. Wells Fargo & Company started coverage on shares of Metsera in a research report on Friday, June 20th. They set an “overweight” rating and a $65.00 target price for the company. Finally, Bank of America upped their price objective on shares of Metsera from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $58.50.

Metsera Price Performance

Shares of MTSR stock opened at $52.50 on Wednesday. The company’s 50 day moving average is $36.09 and its 200 day moving average is $29.68. Metsera has a 52-week low of $12.30 and a 52-week high of $54.47.

Metsera (NASDAQ:MTSR) last issued its quarterly earnings data on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Institutional Trading of Metsera

Several large investors have recently bought and sold shares of MTSR. Alphabet Inc. purchased a new stake in Metsera during the 1st quarter valued at about $135,059,000. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Metsera during the 1st quarter worth approximately $78,748,000. Wellington Management Group LLP acquired a new stake in shares of Metsera during the 1st quarter worth approximately $65,382,000. Alpha Wave Global LP acquired a new stake in Metsera in the 1st quarter valued at approximately $64,894,000. Finally, Price T Rowe Associates Inc. MD acquired a new stake in Metsera in the 1st quarter valued at approximately $42,395,000.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.